Duloxetine-related posterior reversible encephalopathy syndrome: A case report

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin–norepinephrine reuptake inhibitor such as duloxetine is unclear. METHODS: We report on a patient who developed PRES with a coma and myoclonus relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zappella, Nathalie, Perier, François, Pico, Fernando, Palette, Catherine, Muret, Alexandre, Merceron, Sybille, Girbovan, Andrei, Marquion, Fabien, Legriel, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370806/
https://www.ncbi.nlm.nih.gov/pubmed/27537580
http://dx.doi.org/10.1097/MD.0000000000004556
Descripción
Sumario:BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin–norepinephrine reuptake inhibitor such as duloxetine is unclear. METHODS: We report on a patient who developed PRES with a coma and myoclonus related to hypertensive encephalopathy a few days after starting duloxetine treatment. Magnetic resonance imaging was performed and catecholamine metabolites assayed. RESULTS: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsant therapy. CONCLUSIONS: The clinical history, blood and urinary catecholamine and serotonin levels, and response to treatment strongly suggest that PRES was induced by duloxetine. Duloxetine should be added to the list of causes of PRES.